Resveratrol and its oligomers: modulation of sphingolipid metabolism and signaling in disease

Keng Gat Lim, Alexander I. Gray, Nahoum G. Anthony, Simon P. MacKay, Susan Pyne, Nigel J. Pyne

Research output: Contribution to journalArticlepeer-review

16 Citations (Scopus)
532 Downloads (Pure)


Resveratrol, a natural compound endowed with multiple health-promoting effects, has received much attention given its potential for the treatment of cardiovascular, inflammatory, neurodegenerative, metabolic and age-related diseases. However, the translational potential of resveratrol has been limited by its specificity, poor bioavailability and uncertain toxicity. In recent years, there has been an accumulation of evidence demonstrating that resveratrol modulates sphingolipid metabolism. Moreover, resveratrol forms higher order oligomers that exhibit better selectivity and potency in modulating sphingolipid metabolism. This review evaluates the evidence supporting the modulation of sphingolipid metabolism and signaling as a mechanism of action underlying the therapeutic efficacy of resveratrol and oligomers in diseases, such as cancer.
Original languageEnglish
Pages (from-to)2213-2232
Number of pages20
JournalArchives of Toxicology
Issue number12
Early online date25 Oct 2014
Publication statusPublished - 25 Oct 2014


  • resveratrol oligomers
  • resveratrol
  • sphingolipid
  • disease
  • cancer
  • drug discovery


Dive into the research topics of 'Resveratrol and its oligomers: modulation of sphingolipid metabolism and signaling in disease'. Together they form a unique fingerprint.

Cite this